Loading...
XSHE
300463
Market cap795mUSD
Jul 10, Last price  
8.94CNY
1D
0.11%
1Q
-17.83%
Jan 2017
-63.58%
IPO
-39.44%
Name

Maccura Biotechnology Co Ltd

Chart & Performance

D1W1MN
XSHE:300463 chart
P/E
P/S
2.51
EPS
Div Yield, %
1.16%
Shrs. gr., 5y
1.64%
Rev. gr., 5y
-10.27%
Revenues
2.15b
-15.46%
521,308,317606,154,699779,426,580934,846,0791,065,169,0301,488,780,8841,969,983,7282,685,304,9453,222,956,0193,703,877,0053,980,647,1833,608,411,8952,895,769,5112,548,756,6772,154,836,895
Net income
-36m
L
120,415,498158,209,364193,155,929226,210,935251,043,600312,022,762374,132,216444,928,513525,262,646793,917,991956,604,412708,180,365312,618,563126,805,277-35,826,985
CFO
602m
-4.94%
85,546,596110,959,27298,392,339115,090,08433,183,26349,315,14779,033,594193,905,904459,516,3111,094,048,8101,616,683,215843,216,884912,088,535633,798,557602,478,603
Dividend
May 28, 20250.104 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
IPO date
May 28, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT